Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Several companies presented findings at the American Academy of Dermatology's annual meeting (Feb. 16-18, San Diego) indicating that…
By Richa Singh bio
As labs face an increasingly challenging reimbursement environment, more providers are doubling down on out-of-network strategies to maximize on collections opportunities…
By Jeff Myers bio
Accumen Inc. is pleased to announce the launch of the 17th Annual National Hospital and Health System Laboratory and Outreach Survey. The survey is designed to capture intelligence on…
From - Diagnostic Testing & Emerging Technologies
Dermatopathologists are increasingly using molecular testing for diagnosis of skin cancer samples. Yet, this adoption remains more concentrated in…
From - Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration (FDA) recently approved the first blood test to evaluate concussions in adults…
From - Diagnostic Testing & Emerging Technologies
A blood-based screening test capable of detecting multiple forms of early cancer just took one step closer to becoming a reality. A study published…